Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

被引:191
|
作者
Tong, Xiao [1 ]
Chase, Robert [1 ]
Skelton, Angela [1 ]
Chen, Tong [1 ]
Wright-Minogue, Jackie [1 ]
Malcolm, Bruce A. [1 ]
机构
[1] Schering Plough Res Inst, Dept Virol, Kenilworth, NJ 07033 USA
关键词
hepatitis C virus; protease; inhibitor; resistance; antiviral;
D O I
10.1016/j.antiviral.2005.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A 156S mutations conferred low to moderate levels of resistance (< 20-fold). Longer exposure (> 10 passages) or selection with higher levels of compound led to the selection of a more resistant variant, A156T (> 100-fold). [Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279(17), 17508-17514; Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H., Molla, A., 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266.] Combination with IFN-alpha drastically reduced the number of emergent colonies. Resistant colonies showed no change in sensitivity to IFN-alpha. Although the A156T mutation conferred the highest level of resistance to SCH503034, it significantly reduced the colony formation efficiency (CFE) of the mutant replicon RNA, and rendered replicon cells less fit than those bearing wild-type replicons. Replicon cells bearing mutation A156S were less fit than wild-type in co-culture growth competition assays but showed no impact on CFE. The V170A mutation, on the other hand, did not affect replicon fitness in either assay, which was consistent with its emergence as the dominant mutant after 12 months of continuous selection. The reduced fitness of the most resistant variant suggests that it may be rare in naive patients and that development of high-level resistance may be slow. Combination therapy with IFN-alpha should also greatly reduce the potential emergence of resistance. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [1] SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic impairment
    Preston, R. A.
    Alonso, A. B.
    Feely, W.
    Gupta, S.
    Deckman, D.
    Marchisin, D.
    Kantesaria, B.
    Hughes, E.
    [J]. JOURNAL OF HEPATOLOGY, 2007, 46 : S207 - S207
  • [2] Identification of HCV protease inhibitor resistance mutations by selection pressure-based method
    Qiu, Ping
    Sanfiorenzo, Vincent
    Curry, Stephanie
    Guo, Zhuyan
    Liu, Shaotang
    Skelton, Angela
    Xia, Ellen
    Cullen, Constance
    Ralston, Robert
    Greene, Jonathan
    Tong, Xiao
    [J]. NUCLEIC ACIDS RESEARCH, 2009, 37 (10)
  • [3] Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
    Cheng, K. -C.
    Korfmacher, Walter A.
    White, Ronald E.
    Njoroge, F. George
    [J]. PERSPECTIVES IN MEDICINAL CHEMISTRY, 2007, 1 : 1 - 9
  • [4] Characterization of resistance mutations against HCV ketoamide protease inhibitors
    Tong, Xiao
    Bogen, Stephane
    Chase, Robert
    Girijavallabhan, V.
    Guo, Zhuyan
    Njoroge, R. George
    Prongay, Andrew
    Saksena, Anil
    Skelton, Angela
    Xia, Ellen
    Ralston, Robert
    [J]. ANTIVIRAL RESEARCH, 2008, 77 (03) : 177 - 185
  • [5] In vitro resistance mutations against VX-950 and BILN 2061, two HCV protease inhibitor clinical candidates: Single-resistance, cross-resistance, and fitness
    Lin, C
    Rao, BG
    Luong, YP
    Fulghum, JR
    Brennan, DL
    Wei, YY
    Frantz, JD
    Lippke, J
    Hsiao, HM
    Ma, S
    Lin, K
    Maxwell, JP
    Cottrell, KM
    Gates, CA
    Perni, RB
    Kwong, AD
    [J]. HEPATOLOGY, 2004, 40 (04) : 404A - 404A
  • [6] Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation
    Zhang, J
    Gupta, S
    Rouzier, R
    Calzetta, A
    Cutler, DL
    [J]. HEPATOLOGY, 2005, 42 (04) : 535A - 535A
  • [7] Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
    Shang, Luqing
    Lin, Kai
    Yin, Zheng
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (05) : 694 - 703
  • [8] A systematic analysis of the fitness effects of mutations associated with resistance to protease inhibitors
    Henderson, GJ
    Parkin, N
    Swanstrom, R
    [J]. ANTIVIRAL THERAPY, 2005, 10 (04) : S165 - S165
  • [9] A systematic analysis of the fitness effects of mutations associated with resistance to protease inhibitors
    Henderson, GJ
    Parkin, N
    Swanstrom, R
    [J]. ANTIVIRAL THERAPY, 2005, 10 : S165 - S165
  • [10] Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
    Flint, Mike
    Mullen, Stanley
    Deatly, Anne M.
    Chen, Wei
    Miller, Lynn Z.
    Ralston, Robert
    Broom, Colin
    Emini, Emilio A.
    Howe, Anita Y. M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) : 401 - 411